Centene Corporation (NYSE: CNC): Centene Corporation (“Centene” or the “Company”) and certain of the Company’s senior executives have been sued for violations of the federal securities laws. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Centene securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned: Lunstrum v. Centene Corporation, et al., No. 25-cv-05659.

If you incurred losses on your investments in Centene, you are encouraged to submit your information.
 
Why Was Centene Sued for Securities Fraud?
 
Centene is a healthcare company that focuses on providing services to consumers enrolled in government-sponsored healthcare programs like Medicaid and Medicare, as well as those that purchase insurance under the Affordable Care Act from the Health Insurance Marketplace.
 
On December 12, 2024, Centene announced financial guidance for fiscal year 2025 which the company said reflected “[s]tability in earnings power in the face of unprecedented headwinds.” Next, on February 4, 2025, Centene increased its 2025 guidance due to enrollment “overperformance.” Then, on April 25, 2025, Centene again increased 2025 guidance due to continued strong growth in enrollment and retention, while touting the “progress we are making as an organization while navigating a dynamic policy landscape.”  
 
In truth, the majority of the market that Centene serves was experiencing lower than expected enrollment growth and increased morbidity rates, or frequency of disease and illness.   
 
The Stock Declines as the Truth Is Revealed
 
On July 1, 2025, Centene abruptly withdrew its previous guidance after reviewing an independent actuarial report from Wakely Consulting Group which showed that overall market growth in 22 of the 29 states Centene serves was lower than expected and that morbidity in those states was significantly higher than expected. On this news, the price of Centene stock fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025.  

What Are My Rights?
 
If you purchased or otherwise acquired Centene securities, you may ask the Court no later than September 8, 2025, which is the first business day after 60 days from the date of publication of the notice of pendency, to appoint you as Lead Plaintiff through counsel of your choice. To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.

Contact Us
 
If you incurred losses on your investments in Centene, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.  

You can also contact:
Ross Shikowitz
ross@bfalaw.com
212.789.3619

All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
 
Attorney advertising. Past results do not guarantee future outcomes.